These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23042218)

  • 21. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 23. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
    Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
    Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review].
    Strnad J; Bahro M
    Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognition enhancers between treating and doping the mind.
    Lanni C; Lenzken SC; Pascale A; Del Vecchio I; Racchi M; Pistoia F; Govoni S
    Pharmacol Res; 2008 Mar; 57(3):196-213. PubMed ID: 18353672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis.
    Bäckman L; Jones S; Berger AK; Laukka EJ; Small BJ
    Neuropsychology; 2005 Jul; 19(4):520-31. PubMed ID: 16060827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive enhancers for the treatment of neuropsychiatric disorders: clinical and preclinical investigations.
    Kantak KM; Hofmann SG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):113-5. PubMed ID: 21316387
    [No Abstract]   [Full Text] [Related]  

  • 30. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature.
    Conant R; Schauss AG
    Altern Med Rev; 2004 Mar; 9(1):17-31. PubMed ID: 15005642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic target for cognition enhancers: diagnosis and clinical phenomenology.
    Allain H; Boyer P; Kossmann L; Lépine JP; Kanowski S
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():49-51. PubMed ID: 2186412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
    Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
    [No Abstract]   [Full Text] [Related]  

  • 35. Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.
    Small BJ; Gagnon E; Robinson B
    Geriatrics; 2007 Apr; 62(4):19-23. PubMed ID: 17408315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
    Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
    Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The families of cognition enhancers.
    Fröstl W; Maître L
    Pharmacopsychiatry; 1989 Oct; 22 Suppl 2():54-100. PubMed ID: 2690152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards better brain management: nootropics.
    Malik R; Sangwan A; Saihgal R; Jindal DP; Piplani P
    Curr Med Chem; 2007; 14(2):123-31. PubMed ID: 17266573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
    Lipina TV; Palomo V; Gil C; Martinez A; Roder JC
    Neuropharmacology; 2013 Jan; 64():205-14. PubMed ID: 22749842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.